Latest Advances in Lung Cancer Research

A new Phase 3 trial finds Ivonescimab paired with chemotherapy delayed lung cancer progression by 40 % compared to a PD-1 inhibitor combo.

FDA fast-tracks ZL-1310, a promising targeted therapy showing 74% response rate in advanced small cell lung cancer patients with limited treatment options.

AbbVie’s Emrelis, an FDA-approved drug, targets c-Met proteins in NSCLC for effective cancer treatment, marking significant advancements in antibody-drug conjugates (ADCs).

Phase III trial shows mobocertinib performs similarly to chemotherapy for EGFR exon 20 insertion lung cancer patients.

New hope for small cell lung cancer patients as the first patient receives Peluntamig in a clinical trial. This experimental drug targets specific cancer growth pathways.

Final study results show selpercatinib achieves 83% response rate in treatment-naive RET fusion lung cancer patients with durable responses.

Merck halted a lung cancer trial combining vibostolimab with Keytruda due to ineffectiveness and side effects. This setback highlights challenges in developing TIGIT inhibitors for cancer treatment.

Dato-DXd shows promise in treating advanced “HER2-low” lung cancer, slowing progression and potentially extending survival.

Study finds lung cancer patients show distinct lung microbiome profiles versus benign diseases. Analyzing microbial features in bronchoalveolar lavage fluid could serve as minimally invasive biomarker for lung cancer detection, reducing need for biopsies.

LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints. Teliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in patients with previously treated non-small cell lung cancer (NSCLC) with c-Met overexpression.

Experimental gene therapy drug HPN328 is being tested with Tecentriq in a trial to enhance immune response against small cell lung cancer.

This study assessed real-world survival among older patients with non–small-cell lung cancer (NSCLC) and brain metastases (BMs) at diagnosis receiving first-line immune checkpoint inhibitors (ICIs) compared with chemotherapy only.